GSK's RSV Vaccine Wins Expanded Use Approval from FDA

• Arexvy now covers a significantly expanded age range, from its previous approval for adults 60+ and at-risk adults 50-59
• Approximately 21 million U.S. adults under age 50 have at least one risk factor for severe RSV infection, representing a substantial new market
• GSK faces competition from Moderna's mRESVIA and Pfizer's Abrysvo in the RSV vaccine market, with European regulators also considering broader approval for adults 18+

GSK Receives FDA Approval to Expand RSV Vaccine to Younger Adults

British pharmaceutical company GSK announced on March 13 that the U.S. Food and Drug Administration has expanded approval for its respiratory syncytial virus (RSV) vaccine, Arexvy, to include at-risk adults aged 18 to 49. Previously, the vaccine was only approved for adults 60 and older, and at-risk individuals aged 50 to 59.

Key Market Details:

The expansion addresses a significant market opportunity, with an estimated 21 million American adults under 50 having at least one risk factor for severe RSV infection. RSV is a common seasonal respiratory virus and a leading cause of pneumonia and death among infants and older adults.

Competitive Landscape:

GSK's Arexvy faces competition in the RSV vaccine market from Moderna's mRESVIA and Pfizer's Abrysvo. The expanded approval strengthens GSK's competitive position in this growing segment.

Regulatory Progress:

In December, a European Medicines Agency panel recommended broader approval for Arexvy for all adults over 18, indicating potential for international market expansion beyond the U.S.

Market Implications:

This FDA decision significantly expands GSK's addressable market for Arexvy, potentially capturing millions of younger at-risk patients who were previously ineligible. The approval positions GSK favorably in the competitive RSV vaccine landscape and could drive substantial revenue growth. The regulatory momentum in both U.S. and European markets suggests strong confidence in the vaccine's safety and efficacy profile across age groups, which may positively impact GSK's pharmaceutical portfolio performance.